CogState Aandeel

CogState EBITDA

Delisted·15 jun 2026

De EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) van CogState (CGS.AX) per 15 aug 2026 bedraagt 15,71 Miljoen USD. In het voorgaande jaar bedroeg EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) 9,51 Miljoen USD — een verandering van 65,19% (hoger).

EBITDA

15,71 MiljoenUSD

YoY

65,19%

Laatst bijgewerkt:

EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) van CogState is 2026 15,71 Miljoen USD. EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) van CogState was 2025 9,51 Miljoen USD. Het is daarmee 65,19% hoger lager dan het jaar ervoor.
Access this data via the Eulerpool API

CogState Aandelenanalyse

Wat doet CogState? CogState Ltd is an Australian company specializing in the development of innovative cognitive tests. The company was founded in 1999 and is based in Melbourne, Australia. It conducts computer-based cognitive tests to gather information about the cognitive functioning of patients and athletes. The CogState tests are specifically designed to measure cognitive abilities in areas such as perception, reaction time, memory, and attention. The business model of CogState is based on the development, marketing, and sale of cognitive test products. The company generates a significant portion of its revenue through licensing its tests to pharmaceutical and biotech companies that want to test their medications or therapies more effectively. CogState also has a strong presence in the sports industry, offering its tests to sports teams and individual athletes. CogState was founded in 1999 by Paul Maruff, a neuropsychologist, who was searching for better and more effective ways to conduct cognitive tests. Initially, the tests developed by CogState were exclusively for medical research, but it was quickly discovered that they could be useful in other areas as well. In 2004, Richard Kimber joined the company as CEO and Chairman, bringing his experience from the biotechnology industry. CogState offers a variety of cognitive tests for various applications, including clinical trials, sports performance analysis, and brain injury treatment. The tests are licensed by different companies and organizations that use them to test the effects of medications and therapies on cognitive functions or to assess performance and injuries in sports. One example of a CogState product is the AX Continuous Tracker Test. This test was developed for clinical use and allows for continuous and accurate measurement of cognitive functions in patients with psychiatric and neurological disorders. Another application is the SPARQ test for athletes, which allows for the measurement and improvement of athletes' cognitive abilities. In summary, CogState Ltd is a leading company in the field of cognitive tests. The company specializes in developing innovative cognitive tests for the specific requirements of pharmaceutical and biotech companies, as well as sports organizations. The tests are used worldwide by various organizations and have a significant impact on the treatment of psychiatric and neurological disorders, as well as performance and injury analysis in sports. CogState is een van de meest populaire bedrijven op Eulerpool.

Veelgestelde vragen over het aandeel CogState

EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) van CogState bedraagt 15,71 Miljoen USD in 2026.

EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) van CogState is veranderd van 9,51 Miljoen USD naar 15,71 Miljoen USD, wat een verandering van 65,19% vertegenwoordigt. De waarde is hoger dan het vorige jaar.

Op Eulerpool vindt u de volledige historische ontwikkeling van EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) CogState sinds 2006 – met jaarlijkse waarden, grafieken en gedetailleerde analyse.

EBITDA meet de operationele prestaties vóór de impact van de financiële structuur, de belastingomgeving en niet-kasmatige afschrijvingskosten.

EBITDA = EBIT + Afschrijvingen en amortisaties

USD van EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) is een belangrijke factor voor beleggers. Veranderingen in deze maatstaf kunnen sterke signalen geven voor toekomstige koersontwikkelingen.

Access this data via the Eulerpool API

Winst-en-verliesrekening — CogState

Alle kengetallen — CogState